Daewoong Pharm’s botulinum toxin Nabota sees surge in overseas sales

Daewoong Pharmaceutical’s Nabota [Courtesy of Daewoong Pharm]

Daewoong Pharmaceutical’s Nabota, a botulinum toxin product, has surpassed the 80 percent mark in overseas sales, marking a new milestone for the South Korean pharmaceutical company. This achievement is attributed to the relentless pursuit of a global market-centric sales strategy since its initial launch.

According to the company on Tuesday, the cumulative overseas sales of Nabota amounted to 93.5 billion won out of a total of 113.3 billion won in sales up to the third quarter of this year. The overseas sales, which remained at 61 percent in 2021, escalated to 77 percent last year and surged to 83 percent in the current year based on third-quarter cumulative figures.

Out of Nabota’s global sales, 44.5 billion won stemmed from the U.S. market. Daewoong Pharm achieved an 11 percent market share in the U.S. market within just two years of selling the brand named Jeuveau through its partner, Evolus, starting in 2020.